Sweet’s syndrome associated with FLT3 inhibition

Saved in:
Bibliographic Details
Main Authors: Riyad N.H. Seervai, MD, PhD, Elena Paz Munoz, BS, S. Caleb Freeman, MD, Ronan I. Swords, MD, PhD, Kevin P. White, MD, Jesse J. Keller, MD, MCR
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:JAAD Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352512624003801
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846148895519801344
author Riyad N.H. Seervai, MD, PhD
Elena Paz Munoz, BS
S. Caleb Freeman, MD
Ronan I. Swords, MD, PhD
Kevin P. White, MD
Jesse J. Keller, MD, MCR
author_facet Riyad N.H. Seervai, MD, PhD
Elena Paz Munoz, BS
S. Caleb Freeman, MD
Ronan I. Swords, MD, PhD
Kevin P. White, MD
Jesse J. Keller, MD, MCR
author_sort Riyad N.H. Seervai, MD, PhD
collection DOAJ
format Article
id doaj-art-91867e03554c40a387d982f63a7a9036
institution Kabale University
issn 2352-5126
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series JAAD Case Reports
spelling doaj-art-91867e03554c40a387d982f63a7a90362024-11-30T07:11:16ZengElsevierJAAD Case Reports2352-51262024-12-01548992Sweet’s syndrome associated with FLT3 inhibitionRiyad N.H. Seervai, MD, PhD0Elena Paz Munoz, BS1S. Caleb Freeman, MD2Ronan I. Swords, MD, PhD3Kevin P. White, MD4Jesse J. Keller, MD, MCR5Department of Dermatology, Oregon Health & Science University, Portland, Oregon; Correspondence to: Riyad N.H. Seervai, MD, PhD, Department of Dermatology, Oregon Health & Science University, 3303 SW Bond Ave, CHH1 16th Floor, Portland, OR 97239.Department of Dermatology, Oregon Health & Science University, Portland, OregonDepartment of Dermatology, Oregon Health & Science University, Portland, OregonDivision of Hematology/Oncology, Department of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OregonDepartment of Dermatology, Oregon Health & Science University, Portland, OregonDepartment of Dermatology, Oregon Health & Science University, Portland, Oregonhttp://www.sciencedirect.com/science/article/pii/S2352512624003801cutaneous toxicityFLT3 kinase inhibitorgilteritinibneutrophilic dermatosisoncodermatologyquizartinib
spellingShingle Riyad N.H. Seervai, MD, PhD
Elena Paz Munoz, BS
S. Caleb Freeman, MD
Ronan I. Swords, MD, PhD
Kevin P. White, MD
Jesse J. Keller, MD, MCR
Sweet’s syndrome associated with FLT3 inhibition
JAAD Case Reports
cutaneous toxicity
FLT3 kinase inhibitor
gilteritinib
neutrophilic dermatosis
oncodermatology
quizartinib
title Sweet’s syndrome associated with FLT3 inhibition
title_full Sweet’s syndrome associated with FLT3 inhibition
title_fullStr Sweet’s syndrome associated with FLT3 inhibition
title_full_unstemmed Sweet’s syndrome associated with FLT3 inhibition
title_short Sweet’s syndrome associated with FLT3 inhibition
title_sort sweet s syndrome associated with flt3 inhibition
topic cutaneous toxicity
FLT3 kinase inhibitor
gilteritinib
neutrophilic dermatosis
oncodermatology
quizartinib
url http://www.sciencedirect.com/science/article/pii/S2352512624003801
work_keys_str_mv AT riyadnhseervaimdphd sweetssyndromeassociatedwithflt3inhibition
AT elenapazmunozbs sweetssyndromeassociatedwithflt3inhibition
AT scalebfreemanmd sweetssyndromeassociatedwithflt3inhibition
AT ronaniswordsmdphd sweetssyndromeassociatedwithflt3inhibition
AT kevinpwhitemd sweetssyndromeassociatedwithflt3inhibition
AT jessejkellermdmcr sweetssyndromeassociatedwithflt3inhibition